Can Clovinol (clove extract) lower blood sugar levels after meals in healthy volunteers?

ISRCTN ISRCTN15680985
DOI https://doi.org/10.1186/ISRCTN15680985
Secondary identifying numbers AKCN-CLS_01/14
Submission date
21/09/2018
Registration date
28/09/2018
Last edited
09/05/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
The main energy source the body uses is sugar (i.e. glucose), which is derived from the food we eat. The amount of sugar in our blood (i.e. blood glucose levels) is an important indicator of overall health. Both too much sugar (hyperglycemia) and too little sugar (hypoglycemia) in the blood is linked with negative effects on health. Fasting blood sugar is measured when someone has not eaten or drunk anything (except water) for at least 8 hours. Normal fasting blood sugar levels should be below 100 mg/dL. Prediabetes is characterized by fasting blood sugar levels between 100 to 125 mg/dL, and diabetes is when fasting blood sugar is greater than 125 mg/dL. When we eat, our blood sugar increases, and then within 2 to 3 hours blood sugar should return to the level it was before a meal. The amount of sugar in our blood after we eat is called the postprandial blood sugar level. This measurement of blood sugar is also an important indicator of overall health and can be an early sign of abnormal blood sugar control.
Previous studies have identified that clove extract can play a role in helping to manage blood glucose levels. The main objective of this study is to test whether a specialized extract of clove bud, Clovinol®, can help control postprandial blood sugar.

Who can participate?
Individuals who are between 25 and 35 years old, not taking any medication, not obese, and have preprandial (before eating) blood sugar levels below 125 mg/dL.

What does the study involve?
Participants will need to maintain their typical South Indian diet and complete their breakfast by 8 am, eat lunch at 12 pm, and take a Clovinol® capsule immediately after lunch throughout this 30-day study. Between breakfast and lunch, participants should have no snacks or drinks (except water). On specified days of the study, blood sugar will be measured using a digital glucometer immediately before lunch and 2 hours after the start of their lunch.

What are the possible benefits and risks of participating?
Potential benefits include reductions in blood glucose after a meal, which can possibly reduce post-meal fatigue. Potential side effects are limited, but may include mild stomach discomfort.

Where is the study run, and who is funding the study?
This study is funded by and will be conducted at the R&D Center of Akay Flavours & Aromatics Ltd. in Kerala, India.

When is the study starting and how long is it expected to run for?
The study is expected to start in September of 2014 and continue for 30 days.

Who is the main contact?
The main contact is Dr. Krishnakumar IM, Krishnakumar.im@akay-group.com.

Contact information

Dr IM Krishnakumar
Public

Malaidamthuruthu P. O.
Ernakulam
Cochin
683561
India

ORCiD logoORCID ID 0000-0003-0594-7650

Study information

Study designSingle-center open-label interventional pilot study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Home
Study typePrevention
Participant information sheet No participant information sheet available
Scientific titleEffects of Clovinol on random blood sugar in healthy and pre-diabetic adults - an open-label pilot study
Study objectivesType 2 diabetes (T2D) is a global pandemic, and contributes significantly to the increasing incidence of other conditions such as cardiovascular disease. While diabetes screening typically relies on assessment of fasting blood glucose, this may not detect subtle early manifestations of abnormal glucose metabolism. One such early manifestation is impaired glucose tolerance which can precede T2D by many years and is a risk factor for all-cause mortality. Postprandial plasma glucose measured 2 hours after the start of a meal is a good indicator of the overall status of glucose metabolism. Clove (Syzygium aromaticum L.) and its essential oils (eugenol and acetyl eugenol) have been shown in preclinical studies to modulate pathways involved in glucose metabolism. The objective of this pilot study is to test whether Clovinol could influence glucose metabolism. We will evaluate the effect of Clovinol® supplementation on preprandial glucose levels and 2-h PPG levels in otherwise healthy volunteers who have preprandial glucose levels less than 125 mg/dL. This study will test the hypothesis that daily supplementation with Clovinol will reduce pre- and post-prandial blood glucose by 5 and 40 mg/dL, respectively.
Ethics approval(s)Sri Rama Hospital ethics committee, 08/08/2014, ECR/184/Indt/KA /2014
Health condition(s) or problem(s) studiedPrediabetes
Intervention250 mg Clovinol, a hydroethanolic water-soluble exract of unopened clove bud (Syzygium aromaticum L.), administered in one gelatin capsule once daily immediately after lunch for 30 days
Intervention typeSupplement
Primary outcome measureBlood glucose measured with a digital glucometer 2 hours after lunch (post-prandial) measured on days 1, 12, 24 and 30. Day 1 is without Clovinol.
Secondary outcome measuresBlood glucose measured with a digital glucometer immediately before lunch (pre-prandial) measured on days 1, 12, 24 and 30. Day 1 is without Clovinol.
Overall study start date24/03/2014
Completion date23/10/2014

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
SexBoth
Target number of participantsAt least ten subjects shall be included in this open label pilot study
Total final enrolment13
Key inclusion criteria1. Healthy
2. Non-obese
3. Aged 25 - 35 years
4. Blood glucose below 125 mg/dL
Key exclusion criteria1. Take any medication
2. Obese
3. Have diabetes
Date of first enrolment05/09/2014
Date of final enrolment20/09/2014

Locations

Countries of recruitment

  • India

Study participating centre

R&D Center, Akay Flavours & Aromatics Pvt Ltd
Ambunadu, Malaidamthirith P O
Ernakulum
683561
India

Sponsor information

Akay Flavours & Aromatics Pvt. Ltd.
Industry

Malaidamthuruthu P. O., Ernakulam
Cochin
683561
India

Funders

Funder type

Not defined

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date31/12/2018
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination plan
IPD sharing planThe datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 07/05/2019 09/05/2019 Yes No

Editorial Notes

09/05/2019: Publication reference and total final enrolment number added.